{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T09:10:10Z","timestamp":1766049010607,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,8,18]],"date-time":"2018-08-18T00:00:00Z","timestamp":1534550400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s10157-018-1628-5","type":"journal-article","created":{"date-parts":[[2018,8,18]],"date-time":"2018-08-18T07:38:56Z","timestamp":1534577936000},"page":"244-250","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Positive effects of single-daily high-dose mizoribine therapy after cyclophosphamide in young children with steroid-dependent nephrotic syndrome"],"prefix":"10.1007","volume":"23","author":[{"given":"Akira","family":"Mizutani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2957-3705","authenticated-orcid":false,"given":"Shuichiro","family":"Fujinaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Sakuraya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daishi","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,18]]},"reference":[{"key":"1628_CR1","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1007\/s00467-013-2553-1","volume":"28","author":"S Fujinaga","year":"2013","unstructured":"Fujinaga S, Endo A, Ohtomo Y, Ohtsuka Y, Shimizu T. Uncertainty in management of childhood-onset idiopathic nephrotic syndrome: is the long-term prognosis really favorable? Pediatr Nephrol. 2013;28:2235\u20138.","journal-title":"Pediatr Nephrol"},{"key":"1628_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s10157-014-1030-x","volume":"19","author":"K Ishikura","year":"2015","unstructured":"Ishikura K, Matsumoto S, Sako M, Tsuruga K, Nakanishi K, Kamei K, Saito H, Fujinaga S, Hamasaki Y, Chikamoto H, Ohtsuka Y, Komatsu Y, Ohta T, Nagai T, Kaito H, Kondo S, Ikezumi Y, Tanaka S, Kaku Y, Iijima K, Japanese Society for Pediatric Nephrology, Japanese Society for Pediatric Nephrology. Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: medical therapy. Clin Exp Nephrol. 2015;19:6\u201333.","journal-title":"Clin Exp Nephrol"},{"key":"1628_CR3","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/kisup.2012.16","volume":"2","author":"Kidney Disease Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group","year":"2012","unstructured":"Kidney Disease Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis: Steroid-sensitive nephrotic syndrome in children. Kidney Int Suppl. 2012;2:163\u201371.","journal-title":"Kidney Int Suppl"},{"key":"1628_CR4","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00467-010-1707-7","volume":"26","author":"S Fujinaga","year":"2011","unstructured":"Fujinaga S, Hirano D, Nishizaki N, Someya T, Ohtomo Y, Ohtsuka Y, Shimizu T, Kaneko K. Single daily high-dose mizoribine therapy for children with steroid-dependent nephrotic syndrome prior to cyclosporine administration. Pediatr Nephrol. 2011;26:479\u201383.","journal-title":"Pediatr Nephrol"},{"key":"1628_CR5","doi-asserted-by":"publisher","first-page":"251","DOI":"10.5414\/CN107500","volume":"78","author":"S Fujinaga","year":"2012","unstructured":"Fujinaga S, Endo A, Watanabe T, Hirano D, Ohtomo Y, Shimizu T, Kaneko K. Maintenance therapy with single-daily, high-dose mizoribine after cyclophosphamide therapy for prepubertal boys with severe steroid-dependent nephrotic syndrome. Clin Nephrol. 2012;78:251\u20132.","journal-title":"Clin Nephrol"},{"key":"1628_CR6","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/ki.1978.23","volume":"13","author":"International Study of Kidney Disease in Children","year":"1978","unstructured":"International Study of Kidney Disease in Children. Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children. Kidney Int. 1978;13:159\u201365.","journal-title":"Kidney Int"},{"key":"1628_CR7","doi-asserted-by":"publisher","first-page":"3956","DOI":"10.1093\/ndt\/gfq318","volume":"25","author":"K Ishikura","year":"2010","unstructured":"Ishikura K, Yoshikawa N, Hattori S, Sasaki S, Iijima K, Nakanishi K, Matsuyama T, Yata N, Ando T, Honda M, for Japanese Study Group of Renal Disease in Children. Treatment with microemulsified cyclosporine in children with frequently relapsing nephrotic syndrome. Nephrol Dial Transpl. 2010;25:3956\u201362.","journal-title":"Nephrol Dial Transpl"},{"key":"1628_CR8","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2215\/CJN.13071212","volume":"9","author":"K Iijima","year":"2014","unstructured":"Iijima K, Sako M, Oba MS, Ito S, Hataya H, Tanaka R, Ohwada Y, Kamei K, Ishikura K, Yata N, Nozu K, Honda M, Nakamura H, Nagata M, Ohashi Y, Nakanishi K, Yoshikawa N, Japanese Study Group of Kidney Disease in Children. Cyclosporine C2 monitoring for the treatment of frequently relapsing nephrotic syndrome in children: a multicenter randomized phase II trial. Clin J Am Soc Nephrol. 2014;9:271\u20138.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1628_CR9","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.2215\/CJN.00110112","volume":"7","author":"K Ishikura","year":"2012","unstructured":"Ishikura K, Yoshikawa N, Nakazato H, Sasaki S, Iijima K, Nakanishi K, Matsuyama T, Ito S, Yata N, Ando T, Honda M, Japanese Study Group of Renal Disease in Children. Two-year follow-up of a prospective clinical trial of cyclosporine for frequently relapsing nephrotic syndrome in children. Clin J Am Soc Nephrol. 2012;7:1576\u201383.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1628_CR10","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s00467-014-2955-8","volume":"30","author":"K Ishikura","year":"2015","unstructured":"Ishikura K, Yoshikawa N, Nakazato H, Sasaki S, Nakanishi K, Matsuyama T, Ito S, Hamasaki Y, Yata N, Ando T, Iijima K, Honda M, Japanese Study Group of Renal Disease in Children. Morbidity in children with frequently relapsing nephrosis: 10-year follow-up of a randomized controlled trial. Pediatr Nephrol. 2015;30:459\u201368.","journal-title":"Pediatr Nephrol"},{"key":"1628_CR11","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/S0140-6736(85)91387-X","volume":"16","author":"RS Trompeter","year":"1985","unstructured":"Trompeter RS, Lloyd BW, Hicks J, White RH, Cameron JS. Long-term outcome for children with minimal-change nephrotic syndrome. Lancet. 1985;16:368\u201370.","journal-title":"Lancet"},{"key":"1628_CR12","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(89)91266-X","volume":"4","author":"MA Lewis","year":"1989","unstructured":"Lewis MA, Baildom EM, Davis N, Houston IB, Postlethwaite RJ. Nephrotic syndrome: from toddlers to twenties. Lancet. 1989;4:255\u20139.","journal-title":"Lancet"},{"key":"1628_CR13","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1053\/ajkd.2003.50116","volume":"41","author":"F Fakhouri","year":"2003","unstructured":"Fakhouri F, Bocquet N, Taupin P, Presne C, Gagnadoux MF, Landais P, Lesavre P, Chauveau D, Knebelmann B, Broyer M, Gr\u00fcnfeld JP, Niaudet P. Steroid-sensitive nephrotic syndrome: from childhood to adulthood. Am J Kidney Dis. 2003;41:550\u20137.","journal-title":"Am J Kidney Dis"},{"key":"1628_CR14","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jpeds.2005.03.050","volume":"147","author":"EM R\u00fcth","year":"2005","unstructured":"R\u00fcth EM, Kemper MJ, Leumann EP, Laube GF, Neuhaus TJ. Children with steroid-sensitive nephrotic syndrome come of age: long-term outcome. J Pediatr. 2005;147:202\u20137.","journal-title":"J Pediatr"},{"key":"1628_CR15","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1053\/j.ajkd.2007.02.270","volume":"49","author":"HA Kyrieleis","year":"2007","unstructured":"Kyrieleis HA, Levtchenko EN, Wetzels JF. Long-term outcome after cyclophosphamide treatment in children with steroid-dependent and frequently relapsing minimal change nephrotic syndrome. Am J Kidney Dis. 2007;49:592\u20137.","journal-title":"Am J Kidney Dis"},{"key":"1628_CR16","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1093\/ndt\/gfq405","volume":"26","author":"B Cammas","year":"2011","unstructured":"Cammas B, Harambat J, Bertholet-Thomas A, Bouissou F, Morin D, Guigonis V, Bendeddouche S, Afroukh-Hacini N, Cochat P, Llanas B, Decramer S, Ranchin B. Long-term effects of cyclophosphamide therapy in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. Nephrol Dial Transpl. 2011;26:178\u201384.","journal-title":"Nephrol Dial Transpl"},{"key":"1628_CR17","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00467-003-1170-9","volume":"18","author":"U Vester","year":"2003","unstructured":"Vester U, Kranz B, Zimmermann S, Hoyer PF. Cyclophosphamide in steroid-sensitive nephrotic syndrome: outcome and outlook. Pediatr Nephrol. 2003;18:661\u20134.","journal-title":"Pediatr Nephrol"},{"key":"1628_CR18","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s00467-011-1830-0","volume":"26","author":"S Azib","year":"2011","unstructured":"Azib S, Macher MA, Kwon T, Dechartres A, Alberti C, Loirat C, Desch\u00eanes G, Baudouin V. Cyclophosphamide in steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2011;26:927\u201332.","journal-title":"Pediatr Nephrol"},{"key":"1628_CR19","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1136\/adc.65.10.1147","volume":"65","author":"N Ueda","year":"1990","unstructured":"Ueda N, Kuno K, Ito S. Eight and 12 week courses of cyclophosphamide in nephrotic syndrome. Arch Dis Child. 1990;65:1147\u201350.","journal-title":"Arch Dis Child"},{"key":"1628_CR20","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1007\/PL00013435","volume":"14","author":"MJ Kemper","year":"2000","unstructured":"Kemper MJ, Altrogge H, Ludwig K, Timmermann K, M\u00fcller-Wiefel DE. Unfavorable response to cyclophosphamide in steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2000;14:772\u20135.","journal-title":"Pediatr Nephrol"},{"key":"1628_CR21","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1007\/s00467-011-1825-x","volume":"26","author":"A Zagury","year":"2011","unstructured":"Zagury A, de Oliveira AL, de Moraes CA, de Araujo Montalv\u00e3o JA, Novaes RH, de S\u00e1 VM, de Carvalho DDBM, Matuck T. Long-term follow-up after cyclophosphamide therapy in steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2011;26:915\u201320.","journal-title":"Pediatr Nephrol"},{"key":"1628_CR22","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1159\/000314668","volume":"116","author":"S Takeuchi","year":"2010","unstructured":"Takeuchi S, Hiromura K, Tomioka M, Takahashi S, Sakairi T, Maeshima A, Kaneko Y, Kuroiwa T, Nojima Y. The immunosuppressive drug mizoribine directly prevents podocyte injury in puromycin aminonucleoside nephrosis. Nephron Exp Nephrol. 2010;116:e3\u201310.","journal-title":"Nephron Exp Nephrol"},{"key":"1628_CR23","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1681\/ASN.2006070732","volume":"18","author":"A Nakajo","year":"2007","unstructured":"Nakajo A, Khoshnoodi J, Takenaka H, Hagiwara E, Watanabe T, Kawakami H, Kurayama R, Sekine Y, Bessho F, Takahashi S, Swiatecka-Urban A, Tryggvason K, Yan K. Mizoribine corrects defective nephrin biogenesis by restoring intracellular energy balance. J Am Soc Nephrol. 2007;18:2554\u201364.","journal-title":"J Am Soc Nephrol"},{"key":"1628_CR24","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1007\/s00467-005-2025-3","volume":"20","author":"Y Ohtomo","year":"2005","unstructured":"Ohtomo Y, Fujinaga S, Takada M, Murakami H, Akashi S, Shimizu T, Kaneko K, Yamashiro Y. High-dose mizoribine therapy for childhood-onset frequently relapsing steroid-dependent nephrotic syndrome with cyclosporin nephrotoxicity. Pediatr Nephrol. 2005;20:1744\u20139.","journal-title":"Pediatr Nephrol"},{"key":"1628_CR25","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s00467-004-1647-1","volume":"20","author":"Y Kawasaki","year":"2005","unstructured":"Kawasaki Y, Suzuki J, Takahashi A, Isome M, Nozawa R, Suzuki H. Mizoribine oral pulse therapy for steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2005;20:96\u20138.","journal-title":"Pediatr Nephrol"},{"key":"1628_CR26","doi-asserted-by":"publisher","first-page":"179","DOI":"10.5414\/CNP69179","volume":"69","author":"M Fujieda","year":"2008","unstructured":"Fujieda M, Ishihara M, Morita T, Hayashi A, Utsunomiya Y, Ohta T, Sakano T, Wakiguchi H. Effect of oral mizoribine pulse therapy for frequently relapsing steroid-dependent nephrotic syndrome. Clin Nephrol. 2008;69:179\u201384.","journal-title":"Clin Nephrol"},{"key":"1628_CR27","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1046\/j.1523-1755.2000.00168.x","volume":"58","author":"K Yoshioka","year":"2000","unstructured":"Yoshioka K, Ohashi Y, Sakai T, Ito H, Yoshikawa N, Nakamura H, Tanizawa T, Wada H, Maki S. A multicenter trial of mizoribine compared with placebo in children with frequently relapsing nephrotic syndrome. Kidney Int. 2000;58:317\u201324.","journal-title":"Kidney Int"},{"issue":"1","key":"1628_CR28","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1006\/bbrc.2000.3104","volume":"274","author":"S Takahashi","year":"2000","unstructured":"Takahashi S, Wakui H, Gustafsson JA, Zilliacus J, Itoh H. Functional interaction of the immunosuppressant mizoribine with the 14-3-3 protein. Biochem Biophys Res Commun. 2000;274(1):87\u201392.","journal-title":"Biochem Biophys Res Commun"},{"key":"1628_CR29","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1007\/s00467-011-1948-0","volume":"26","author":"S Ito","year":"2011","unstructured":"Ito S, Ikeda H, Harada T, Kamei K, Takahashi E. Cyclophosphamide followed by mizoribine as maintenance therapy against refractory steroid dependent nephrotic syndrome. Pediatr Nephrol. 2011;26:1921\u20132.","journal-title":"Pediatr Nephrol"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10157-018-1628-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-018-1628-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-018-1628-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T23:51:38Z","timestamp":1604793098000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10157-018-1628-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,18]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["1628"],"URL":"https:\/\/doi.org\/10.1007\/s10157-018-1628-5","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"type":"print","value":"1342-1751"},{"type":"electronic","value":"1437-7799"}],"subject":[],"published":{"date-parts":[[2018,8,18]]},"assertion":[{"value":"7 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the Institutional Research Committee and\/or National Research Committee at which the study was conducted(approval number 2018-02-19) with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"Informed consent was obtained from all participants included in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}